Skip to content

Safe medical treatment in Palliative care - Pharmaceutical analysis of palliativ care medication process

Safe medical treatment in Palliative care - Pharmaceutical analysis of palliativ care medication process

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00013591
Enrollment
150
Registered
2018-01-03
Start date
2018-01-03
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Z51.5

Interventions

Group 1: Before-and-after-studies: control group: without pharmacist on station, no intervention Documentation of the medication: - Pre-medication before hospitalization - Medication at first day in

Sponsors

Klinik und Poliklinik für PalliativmedizinKlinikum der Universtität München
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: - incurable disease (malignant or non-malignant) - >18 years - inpatient (St. Josefs-Hospital Wiesbaden oder Helios HSK Wiesbaden) - communication (german/english) - Statement of agreement

Exclusion criteria

Exclusion criteria: Person who are unable to give their consent

Design outcomes

Primary

MeasureTime frame
drug-related problems (inpatient, outpatient) Classification drug related problems (PCNE V8.1)

Secondary

MeasureTime frame
- Deviations between inpatient medication and medication 7 days after discharge from the hospital - Interactions: inpatient (day 2, last day), 7 days after discharge from the hospital - pharmacist visits patient at home 7 days after discharge from the hospital - unplaned admission in the hospital - Change in clinical symptoms

Countries

Germany

Contacts

Public ContactLisa Krumm

Aukamm-Apotheke

lisa.krumm@med.uni-muenchen.de061195016500

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026